<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2042">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05134584</url>
  </required_header>
  <id_info>
    <org_study_id>RenJiH211012</org_study_id>
    <nct_id>NCT05134584</nct_id>
  </id_info>
  <brief_title>Efficacy of Linaclotide in Patients With Overlapping Functional Gastrointestinal Disorders</brief_title>
  <official_title>Efficacy and Safety of Linaclotide in Patients With Overlap of Functional Dyspepsia and Constipation-predominant Irritable Bowel Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>RenJi Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>RenJi Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to assess the efficacy and safety of linaclotide in patients with overlapping&#xD;
      symptoms of both functional dyspepsia (FD) and constipation-predominant irritable bowel&#xD;
      syndrome (IBS-C).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      After being informed about the content and risks of the research, all eligible patients&#xD;
      giving written informed consent will be randomly allocated in a 2:1 ratio to linaclotide&#xD;
      (290μg, once daily) or lactulose (20mL, once daily). Treatment will last consecutively for 4&#xD;
      weeks, and patients' symptoms will be assessed before and after four-week treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2021</start_date>
  <completion_date type="Anticipated">February 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>Participants and investigators were not masked to group assignment. An independent statistician was masked for the data analysis.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment satisfaction assessed by the VAS</measure>
    <time_frame>Week 4</time_frame>
    <description>Treatment satisfaction will be assessed by the Visual Analogue Scale: score 0=not at all, 1=partial relief of general GI symptoms, 2=complete relief of general GI symptoms.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in stool frequency</measure>
    <time_frame>Baseline and Week 4</time_frame>
    <description>Stool frequency will be assessed using bowel movement (BM), spontaneous bowel movement (SBM), complete spontaneous bowel movement (CSBM) during the past 7 days.&#xD;
Change = (Week 4 Score - Baseline Score).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in stool consistency</measure>
    <time_frame>Baseline and Week 4</time_frame>
    <description>Stool consistency will be assessed using Bristol Stool Form Scale (BSFS), which contains 7 types of stool consistency.&#xD;
Change = (Week 4 Score - Baseline Score).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in defecation straining score</measure>
    <time_frame>Baseline and Week 4</time_frame>
    <description>Defecation straining score will be assessed using six-point scale (score 0 = effortless, 5 = extremely laborious).&#xD;
Change = (Week 4 Score - Baseline Score).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in defecation time</measure>
    <time_frame>Baseline and Week 4</time_frame>
    <description>Defecation time will be assessed using approximate duration: less than 15 minutes, 15-30 minutes, more than 30 minutes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in sensation of complete evacuation</measure>
    <time_frame>Baseline and Week 4</time_frame>
    <description>Sensation of complete evacuation will be assessed using five-point scale (score 0 = not at all, 4 = complete totally).&#xD;
Change = (Week 4 Score - Baseline Score).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in lower abdominal discomfort</measure>
    <time_frame>Baseline and Week 4</time_frame>
    <description>Lower abdominal discomfort will be assessed using six-point scale (score 0 = not at all, 5 = extremely severe).&#xD;
Change = (Week 4 Score - Baseline Score).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in lower abdominal pain</measure>
    <time_frame>Baseline and Week 4</time_frame>
    <description>Lower abdominal pain will be assessed using six-point scale (score 0 = not at all, 5 = extremely severe).&#xD;
Change = (Week 4 Score - Baseline Score).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in FD symptoms</measure>
    <time_frame>Baseline and Week 4</time_frame>
    <description>FD symptoms will be assessed using Patient Assessment of Gastrointestinal Disorders-Symptom Severity Index (PAGI-SYM).&#xD;
Change = (Week 4 Score - Baseline Score).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in the anxiety status</measure>
    <time_frame>Baseline and Week 4</time_frame>
    <description>The anxiety status will be assessed using the Generalized Anxiety Disorder scale (GAD-7).&#xD;
Change = (Week 4 Score - Baseline Score).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in the depression status</measure>
    <time_frame>Baseline and Week 4</time_frame>
    <description>The depression status will be assessed using the Patient Health Questionnaire (PHD-9).&#xD;
Change = (Week 4 Score - Baseline Score).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">78</enrollment>
  <condition>Functional Dyspepsia</condition>
  <condition>Constipation-predominant Irritable Bowel Syndrome</condition>
  <arm_group>
    <arm_group_label>linaclotide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in linaclotide group were given with oral, once daily 290 μg linaclotide for consecutively 4 weeks, along with once daily 20 mg omeprazole, three times daily 50 mg Itopride, for the first ten days of the treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>lactulose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients in Lactulose group were given with oral, once daily 20 mL Lactulose for 4 weeks, along with once daily 20 mg omeprazole, three times daily 50 mg Itopride, for the first ten days of the treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Linaclotide</intervention_name>
    <description>290μg once daily, 4 weeks</description>
    <arm_group_label>linaclotide</arm_group_label>
    <other_name>Linzess</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lactulose</intervention_name>
    <description>20mL once daily, 4 weeks</description>
    <arm_group_label>lactulose</arm_group_label>
    <other_name>Duphalac</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Omeprazol</intervention_name>
    <description>20mg twice daily for the first 10 days</description>
    <arm_group_label>lactulose</arm_group_label>
    <arm_group_label>linaclotide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Itopride</intervention_name>
    <description>50mg three times daily for the first 10 days</description>
    <arm_group_label>lactulose</arm_group_label>
    <arm_group_label>linaclotide</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Outpatients&#xD;
&#xD;
          2. Diagnosis of FD (including postprandial distress syndrome [PDS] with or without&#xD;
             epigastric pain syndrome [EPS]) (Rome Ⅲ criteria)&#xD;
&#xD;
          3. Diagnosis of IBS-C (Rome Ⅲ criteria)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Helicobacter Pylori infection&#xD;
&#xD;
          2. GI symptoms caused by taking non-steroidal anti-inflammatory drugs or other agents&#xD;
&#xD;
          3. Pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shengliang Chen</last_name>
    <role>Principal Investigator</role>
    <affiliation>RenJi Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shengliang Chen</last_name>
    <phone>86-21-58752345</phone>
    <email>chenslmd@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>RenJiH</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shengliang Chen</last_name>
      <phone>86-21-58752345</phone>
      <email>chenslmd@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 14, 2021</study_first_submitted>
  <study_first_submitted_qc>November 14, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 26, 2021</study_first_posted>
  <last_update_submitted>November 29, 2021</last_update_submitted>
  <last_update_submitted_qc>November 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>RenJi Hospital</investigator_affiliation>
    <investigator_full_name>Shengliang Chen</investigator_full_name>
    <investigator_title>professor,chief physician</investigator_title>
  </responsible_party>
  <keyword>functional dyspepsia</keyword>
  <keyword>irritable bowel syndrome</keyword>
  <keyword>constipation</keyword>
  <keyword>linaclotide</keyword>
  <keyword>lactulose</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Irritable Bowel Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Constipation</mesh_term>
    <mesh_term>Dyspepsia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lactulose</mesh_term>
    <mesh_term>Linaclotide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

